002252.SZ
上海莱士
SZSE · Healthcare · C 制造业 · CN
CNY 4.81
−0.21%Aug 28, 2026, 03:50 UTC
Shanghai RAAS stated that Guangxi RAAS is in trial production and has not yet officially commenced production.
Source:Aug 24, 2026, 12:17 UTC
Shanghai RAAS reported its first-half 2026 results, with net profit attributable to shareholders of 661 million yuan, down 35.80% year-on-year.
Aug 21, 2026, 12:18 UTC
Shanghai RAAS's subsidiary Guangxi RAAS Biopharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application for Protein C, a treatment for congenital protein C deficiency.
Source:Jul 22, 2026, 10:16 UTC
Shanghai RAAS announced the Phase II clinical trial progress of SR604 injection for congenital factor VII deficiency on the National Medical Products Administration drug trial registration platform.
Source: